Bioenvision (NASDAQ:BIVN)
Historical Stock Chart
From Jun 2019 to Jun 2024
Bioenvision, Inc. (Nasdaq:BIVN) today announced that Dr. Andrew N.
Schiff and Mr. Steven A. Elms have resigned from the Company’s
Board of Directors effective as of July 13, 2007. These departures were
anticipated following the closing of the tender offer contemplated by
the agreement and plan of merger entered into on May 29, 2007 by the
Company, Genzyme Corporation (Nasdaq: GENZ) and Wichita Bio Corporation,
a wholly-owned subsidiary of Genzyme.
Dr. Christopher B. Wood, Chairman and CEO of Bioenvision, stated, “We
sincerely thank Drew and Steve for their dedication to our company over
the past 5+ years. Their support, hard work, and insights have
contributed substantially to the value we have created within
Bioenvision. The significant corporate and drug developments we have
achieved would not have been possible without their direct
contributions, for which we are grateful.”
About Bioenvision
Bioenvision's primary focus is the acquisition, development and
marketing of compounds and technologies for the treatment of cancer.
Bioenvision has a broad pipeline of products for the treatment of
cancer, including: Evoltra®,
Modrenal® (for which
Bioenvision has obtained regulatory approval for marketing in the United
Kingdom for the treatment of post-menopausal breast cancer following
relapse to initial hormone therapy), and other products. Bioenvision is
also developing Suvus®
which is currently in clinical development for refractory chronic
hepatitis C infection. For more information on Bioenvision please visit
our website at www.bioenvision.com.
Certain statements contained in this press release are
"forward-looking" statements, including express or implied statements
regarding the future approval by Bioenvision’s
stockholders of the pending agreement and plan of merger with Genzyme.
Because these statements are subject to risks and uncertainties, actual
results may differ materially from those expressed or implied by such
forward-looking statements. Specifically, factors that could cause
actual results to differ materially from those expressed or implied by
such forward-looking statements include, but are not limited to: risks
associated with whether the merger of Wichita Bio Corporation with and
into Bioenvision will be approved by the stockholders of Bioenvision;
risks associated with the uncertainty as to whether such merger will in
fact occur, risks associated with disruptions from the proposed merger
transaction which may harm relationships with customers, employees,
suppliers and partners; risks associated with the outcome of litigation
and regulatory proceedings to which we are currently a party and may
become a party in the future; risks associated with preclinical and
clinical developments in the biopharmaceutical industry in general and
in Bioenvision's compounds under development in particular; the
potential failure of Bioenvision's compounds under development to prove
safe and effective for treatment of disease; uncertainties inherent in
the early stage of Bioenvision's compounds under development; failure to
successfully implement or complete clinical trials; failure to receive
marketing clearance from regulatory agencies for our compounds under
development; acquisitions, divestitures, mergers, licenses or strategic
initiatives that change Bioenvision's business, structure or
projections; the development of competing products; uncertainties
related to Bioenvision's dependence on third parties and partners; and
those risks described in Bioenvision's filings with the SEC. Bioenvision
assumes no obligation to update any forward-looking statements as a
result of new information or future events or developments, except as
required by law and the statements contained in this press release are
current as of the date of this release only.